title: High sensitivity C-reactive protein and outcomes following percutaneous coronary intervention in contemporary practice.
abstract: BACKGROUND
  High sensitivity C-reactive protein (hsCRP) has been identified as a predictor of adverse cardiovascular outcomes. Whether hsCRP is a useful biomarker for risk stratification in contemporary percutaneous coronary intervention remains unknown.
  
  
  RESULTS
  We conducted a prospective study among 513 patients undergoing non-emergency percutaneous coronary intervention and examined the relationship between pre- and postprocedural hsCRP levels and outcomes. The patients were divided according to the median preprocedural hsCRP level (0.3 mg/dL). Patients with high hsCRP had significantly more adverse clinical characteristics. Preprocedural hsCRP level was an independent predictor of periprocedural myocardial infarction (odds ratio per doubling of hsCRP 1.15 [95% confidence interval, 1.01-1.31]; P=0.038). Unadjusted mortality (29.7% versus 9.9%; P<0.001) and the combined end point of death or myocardial infarction (36.5% versus 16.0%, P<0.001) during a follow-up of 5 years were markedly greater in patients with high preprocedural hsCRP. Similar relationships existed for postprocedural hsCRP. However, after multivariable adjustment, neither preprocedural hsCRP levels (hazard ratio per doubling 0.96 [0.92, 1.00]; P=0.066) nor postprocedural hsCRP levels (hazard ratio 0.98 [0.94, 1.02]; P=0.27) were significantly associated with mortality.
  
  
  CONCLUSIONS
  High hsCRP is associated with a greater independent risk of periprocedural myocardial infarction, as defined by the universal definition, but is not an independent determinant of mortality after percutaneous coronary intervention. Our findings suggest that routine measurement of hsCRP in patients undergoing percutaneous coronary intervention in contemporary practice is unlikely to be beneficial.
authors.affiliation: Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
authors.forename: Joerg
authors.initials: J
authors.lastname: Herrmann
authors.forename: Ryan J
authors.initials: RJ
authors.lastname: Lennon
authors.forename: Gregory W
authors.initials: GW
authors.lastname: Barsness
authors.forename: Gurpreet S
authors.initials: GS
authors.lastname: Sandhu
authors.forename: Rajiv
authors.initials: R
authors.lastname: Gulati
authors.forename: Patricia J M
authors.initials: PJ
authors.lastname: Best
authors.forename: Paul
authors.initials: P
authors.lastname: Sorajja
authors.forename: John F
authors.initials: JF
authors.lastname: Bresnahan
authors.forename: Verghese
authors.initials: V
authors.lastname: Mathew
authors.forename: Malcolm R
authors.initials: MR
authors.lastname: Bell
authors.forename: Abhiram
authors.initials: A
authors.lastname: Prasad
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism*; D016009:Chi-Square Distribution; D003324:Coronary Artery Disease / Q000097:blood / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D005260:Female; D017052:Hospital Mortality; D006801:Humans; D053208:Kaplan-Meier Estimate; D016014:Linear Models; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009203:Myocardial Infarction / Q000209:etiology / Q000401:mortality; D016017:Odds Ratio; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects / Q000401:mortality; D016016:Proportional Hazards Models; D011446:Prospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D002097:C-Reactive Protein